Abstract 90P
Background
Large populations blood-based sequencing studies have revealed that somatic mutations in hematopoietic cells are acquired during aging. This phenomenon, in the absence of cytopenias and dysplastic haematopoiesis, is known as clonal haematopoiesis of indeterminate potential (CHIP). Genes involved in CHIP include ATM and CHEK2, encoding key regulators of DNA repair. These genes are associated with response to anticancer treatments, e.g. poly-ADP ribose polymerase (PARP) inhibitors, and used as biomarkers within clinical trials. We evaluated CHIP mutation frequency in a cohort of patients undergoing evaluation for early phase trials.
Methods
Blood samples (≤60 mL) were taken from patients with solid tumours within the TARGET National study (NCT04723316). Circulating tumour DNA (ctDNA) was sequenced using Foundation Medicine Liquid CDx. Patients consented at Newcastle Hospitals were identified on the TARGET National database. Aberrations in DNMT3A, TET2, JAK2, CHEK2 and ATM that were flagged as not tumoral by the study Molecular Tumour Board were considered as CHIP.
Results
Of 382 patients with 42 different cancer types, 162 (43%) had ≥1 mutation considered as CHIP. CHIP was most frequent in patients aged 50-70 years, showing significant association with ageing (p=0.0016). Mutations were most frequent in lung (17%), prostate (13%) and colorectal (9%) cancer. Alterations of DNMT3A were most common (57%), followed by TET2 (20%), CHEK2 (10%), ATM (9%) and JAK2 (4%). Among patients with CHIP, 109 (67%) had previous platinum-based chemotherapy. No significant relationship was found between CHIP and Platinum-based chemotherapy (p=0.0665). However, in this cohort CHEK2 (80%) and ATM (78%) were the most frequent CHIP alterations (p>0.05).
Conclusions
CHIP was highly prevalent in cancer patients likely due to genotoxic stress and ageing. The rate of mutations was dependant on cancer types and treatment context. The prevalence of mutated DNA repair genes CHEK2 and ATM was increased post-cisplatin exposure. Therefore, the clinical relevance of these alterations as therapeutic targets in patients post platinum-based chemotherapy requires cautious interpretation.
Clinical trial identification
NCT04723316.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Sir Bobby Robson Foundation.
Disclosure
P. Rescigno: Financial Interests, Advisory Board: AstraZeneca, Janssen, Pfizer. C. Oing: Financial Interests, Personal, Invited Speaker, Renal Cancer Expert Panel Case Presentation: Ipsen; Financial Interests, Personal, Invited Speaker, Talk on Pain Management in GU Cancer Patients: Medac; Financial Interests, Personal, Invited Speaker, Case Presentation Soft Tissue Sarcoma: Roche; Financial Interests, Personal, Advisory Board, Ad Board on discussing novel educational events for young haematologists: Novartis; Financial Interests, Personal, Invited Speaker, Science Slam with a presentation on young professional support from oncological societies in Germany: AstraZeneca; Financial Interests, Personal, Advisory Board, AdBoard assessing educational needs for oncology professionals regarding G-CSF use: Sandoz; Financial Interests, Personal, Invited Speaker, Presentation on Burnout and Resilience in medical oncology professionals: Asklepios Hamburg; Financial Interests, Personal, Advisory Board, Larotrectinib use in sarcoma: Bayer; Financial Interests, Personal, Advisory Board, Experiences with Cabo/Nivo as first-line treatment for metastatic RCC: Ipsen; Financial Interests, Personal, Advisory Board, Workshop series on improving customer experience: Pfizer; Non-Financial Interests, Other, Clinical Advisory role in early drug discovery with a fellowship position affiliated with Astex Pharmaceuticals, Cambridge, UK: Astex Pharmaceuticals; Non-Financial Interests, Institutional, Product Samples, Cytotoxic Agent for Preclinical Experiments: PharmaMar. R. Plummer: Financial Interests, Personal, Advisory Board: Pierre Fabre, Bayer, Novartis, BMS, Cybrexa, Ellipses, CV6 Therapeutics, Astex Therapeutics, Sanofi Aventis, Immunocore, Genmab, Medivir, Onexo, Incyte; Financial Interests, Institutional, Royalties, Royalties relating to rucaparib licencing: Clovis Oncology; Financial Interests, Personal, Other, Honorarium as member of IDMC: SOTIO, Alligator Biosciences, AstraZeneca; Financial Interests, Personal, Other, Honoraria as member of IDMC: GSK. A. Greystoke: Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Boehringer Ingelheim, Takeda, Roche, Novartis; Financial Interests, Personal, Invited Speaker: Merck, MSD, Pfizer, Janssen; Financial Interests, Institutional, Local PI: MSD; Financial Interests, Institutional, Coordinating PI: Pfizer, AstraZeneca, Novartis, Achilles; Non-Financial Interests, Advisory Role: National Institute for Health and Clinical Excellence; Non-Financial Interests, Leadership Role, Steering Committee member: British Thoracic Oncology Group; Other, Clinical Lead for Cancer (paid position): North East England and Yorkshire Genomic Laboratory Hub. All other authors have declared no conflicts of interest.
Resources from the same session
1802P - Cost-effectiveness study of atezolizumab (ATZ) vs. durvalumab (DUR) in elderly extensive disease small cell lung cancer (ED-SCLC) patients (pts): Real-world data (RWD) on first-line chemotherapy combined with immune-checkpoint inhibitors (Chemo-ICIs)
Presenter: Ken Yamamoto
Session: Poster session 07
1803P - Analysis of samples from the SCLC REACTION trial: Discovery of biomarkers to optimize treatment
Presenter: Pernelle Lavaud
Session: Poster session 07
1805P - PKD1L1 mutations in small cell lung cancer: A genomic signature for poor prognosis and drug susceptibility
Presenter: Ning Tang
Session: Poster session 07
Resources:
Abstract
1806P - Clinical characteristics and management of small cell lung cancer long survivors
Presenter: Elisa Gobbini
Session: Poster session 07
1807P - Spatial analyses revealed MMP7 as the biomarker of tumor boundary correlated with immune resistance in small cell lung cancer
Presenter: Le Tang
Session: Poster session 07
1809P - Validation of the lung inmune prognostic (LIPI) index in first-line immunotherapy treatment of small cell lung carcinoma
Presenter: Patricia Cruz Castellanos
Session: Poster session 07
1810P - MYC expression defines distinct transcriptomic landscape and affects response to DNA-damaging therapies in SCLC
Presenter: Caterina de Rosa
Session: Poster session 07